Alisertib (MLN8237)

Catalog No.S1133

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Cited by 198 Publications

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )
FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )
Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )
Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2083-2093

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )
Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )
Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015, 17(1)

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )
Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )
Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013, 4(1):80-93

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )
EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features

First orally available inhibitor of Aurora A.

Targets

Aurora A ^[1]
(Cell-free assay)

1.2 nM

In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. ^[1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. ^[2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	M{\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPHNE42KM7:TR?=	NILtSHI4OiCq	NX70TYZYTE2VTx?=	NHXP[IVKSzVyPUCuNFQh\|ryP	MV6yOlE{PjZ6NB?=
LS174T	NFG2WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf4c\|F1OC53IN88US=>	NHjzbJc4OiCq	MmfPSG1UVw>?	NXT0UWQ4UUN3ME2wMlA2KM7:TR?=	NY\rcG9jOjZzM{[2PFQ>
T84	NWrpT3lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPTVI1uOC53IN88US=>	MlrJO\|IhcA>?	NXPhU4tHTE2VTx?=	Mn73TWM2OD1yLkC5JO69VQ>?	MoPkNlYyOzZ4OES=
LS180	M4rPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETrNmoxNjVizszN	NV7tdYN2PzJiaB?=	M1rn[mROW09?	MoP2TWM2OD1zIN88US=>	NUO3W3RyOjZzM{[2PFQ>
SW948	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jtWVAvPSEQvF2=	NUTrPWdZPzJiaB?=	NYnOeXFzTE2VTx?=	MlvJTWM2OD1zIN88US=>	NV6xO2dKOjZzM{[2PFQ>
HCT15	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzHNE42KM7:TR?=	MWe3NkBp	NGLD[FVFVVOR	M3XSeWlEPTB:MD60JO69VQ>?	M2jh[FI3OTN4Nki0
DLD-1	NUWyb5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnkdXVxOC53IN88US=>	MYS3NkBp	MmO2SG1UVw>?	NXf3[JJTUUN3MEywMlgh\|ryP	MlW3NlYyOzZ4OES=
MIP-101	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL0cGExNjVizszN	M1GxN\|czKGh?	M{fhXmROW09?	NITmNmhKSzVyPUGg{txO	NXW4W5F{OjZzM{[2PFQ>
SNU1544	NI\SOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmwMlUh\|ryP	M2G5SVczKGh?	NGjXO4RFVVOR	MYXJR\|UxRTFizszN	MnPmNlYyOzZ4OES=
OCI-Ly10	MXjDfZRwfG:6aXOgRZN{[Xl?		M4riRVczKGh?	NEj4UHZFVVOR	M2T1TmlEPTB;MD6wOVgh\|ryP	MXmyOVg4QDN\|MR?=
SU-DHL2	NUjSTm5xS3m2b4TvfIlkKEG\|c3H5		NYDmZ45EPzJiaB?=	M1u2UWROW09?	MlLTTWM2OD1yLkCxJO69VQ>?	NVr6VFZzOjV6N{izN\|E>
OCI-LY7	NWLRcnl{S3m2b4TvfIlkKEG\|c3H5		NXuz[ZVtPzJiaB?=	MnSySG1UVw>?	NWm4W2lKUUN3ME2wMlA5OSEQvF2=	NFjpbWUzPTh5OEOzNS=>
SU-DHL6	NU\ke5g3S3m2b4TvfIlkKEG\|c3H5		NYfEdZN5PzJiaB?=	M2n0XGROW09?	M4LrVmlEPTB;MD60PFIh\|ryP	Mn\zNlU5Pzh\|M{G=
Jeko-1	NWDEUVVVS3m2b4TvfIlkKEG\|c3H5		NWnm[ZZyPzJiaB?=	MkTCSG1UVw>?	NV7HWIMxUUN3ME2wMlAzQSEQvF2=	NHXkXmEzPTh5OEOzNS=>
JVM-2	M3vkWmN6fG:2b4jpZ{BCe3OjeR?=		MVO3NkBp	Ml\LSG1UVw>?	MXHJR\|UxRTBwMEGg{txO	NXLzbIVFOjV6N{izN\|E>
Rec-1	NULBTGMyS3m2b4TvfIlkKEG\|c3H5		M2HqZVczKGh?	MmDkSG1UVw>?	Ml\ETWM2OD1yLkC4O{DPxE1?	MWCyOVg4QDN\|MR?=
Z-138	NGTvXnpEgXSxdH;4bYMhSXO\|YYm=		MVG3NkBp	MkPxSG1UVw>?	NVPTWWlqUUN3ME2wMlAyOyEQvF2=	MXuyOVg4QDN\|MR?=
H9	MUnDfZRwfG:6aXOgRZN{[Xl?		MWC3NkBp	NGG0b2lFVVOR	MlHCTWM2OD1yLk[g{txO	NV7RVZFOOjV6N{izN\|E>
HH	MYPDfZRwfG:6aXOgRZN{[Xl?		M3Tx[\|czKGh?	NIDPR3lFVVOR	M1jKTmlEPTB;MD63JO69VQ>?	NH3iTJIzPTh5OEOzNS=>
DND41	NGXJelhEgXSxdH;4bYMhSXO\|YYm=		MofiO\|IhcA>?	M3n1d2ROW09?	NU\5NI1ZUUN3ME2wMlEh\|ryP	MXGyOVg4QDN\|MR?=
CCL119	M4TMdGN6fG:2b4jpZ{BCe3OjeR?=		NHTBPWY4OiCq	NW\oe4dwTE2VTx?=	M3vWc2lEPTB;MD6wOlIh\|ryP	NUK5bpljOjV6N{izN\|E>
J.Cam 1.6	NXjqPYxMS3m2b4TvfIlkKEG\|c3H5		MYO3NkBp	MkPXSG1UVw>?	NFrnXJBKSzVyPUCuNVA2KM7:TR?=	M3TyU\|I2QDd6M{Ox
Sup-T1	MXjDfZRwfG:6aXOgRZN{[Xl?		MkPPO\|IhcA>?	Mm\wSG1UVw>?	NULme4ZFUUN3ME2yMlE1OiEQvF2=	NVzMVo9uOjV6N{izN\|E>
Tib 152	NVf3dIJkS3m2b4TvfIlkKEG\|c3H5		MVq3NkBp	M3zOT2ROW09?	MYLJR\|UxRTBwODFOwG0>	NF7GenEzPTh5OEOzNS=>
MCF7	M3fpO2Z2dmO2aX;uJGF{e2G7	NIjZPWQ2KM7:TR?=	MlOxNlQhcA>?	NYD5ZVR3TE2VTx?=	M33a[Wlv\HWlZYOgS\|IwVSCjcoLld5Q>	MoPvNlU5OzR2MEG=
MDA-MB-231	M{HDZWZ2dmO2aX;uJGF{e2G7	MkXUOUDPxE1?	NH62dGszPCCq	MmLPSG1UVw>?	MlvRTY5lfWOnczDHN{9OKGG{cnXzeC=>	MorJNlU5OzR2MEG=
MCF7	MWrGeY5kfGmxbjDBd5NigQ>?	NXjkV2hpPSEQvF2=	MXuyOEBp	MkP0SG1UVw>?	NGT5RVlF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	MXKyOVg{PDRyMR?=
MCF7	Mli4SpVv[3Srb36gRZN{[Xl?	Ml30OUDPxE1?	NXzuRmt4OjRiaB?=	MnGySG1UVw>?	NUDmdmx[TGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzJ?	NIHjS4szPTh\|NESwNS=>
MCF7	NYLHTXpKTnWwY4Tpc44hSXO\|YYm=	MkfpOUDPxE1?	NE[yd4EzPCCq	MXPEUXNQ	NF7iTFVF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx	NYf1d45FOjV6M{S0NFE>
MCF7	M1nTZWZ2dmO2aX;uJGF{e2G7	MX[1JO69VQ>?	MXWyOEBp	M1\KOGROW09?	MnGwTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	Mn7LNlU5OzR2MEG=
MCF7	MWXGeY5kfGmxbjDBd5NigQ>?	MUi1JO69VQ>?	M2DqUlI1KGh?	NYn1fIJ[TE2VTx?=	MWPJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF?	M2jIcFI2QDN2NECx
MDA-MB-231	NYPUT2N7TnWwY4Tpc44hSXO\|YYm=	MXW1JO69VQ>?	NXnufnZrOjRiaB?=	M1vV[mROW09?	M4nxdGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K=	M1LwVVI2QDN2NECx
MDA-MB-231	M{TqXGZ2dmO2aX;uJGF{e2G7	MmPrNUDPxE1?	MoDqNlQhcA>?	M1z0dWROW09?	NIDIendKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>?	NIjMZ\|gzPTh\|NESwNS=>
MDA-MB-231	MmjHSpVv[3Srb36gRZN{[Xl?	NXz0PHZWPSEQvF2=	NXHHS5h1OjRiaB?=	MXzEUXNQ	M{ixNWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG=	NUnWdllEOjV6M{S0NFE>
MDA-MB-231	NYLGem5pTnWwY4Tpc44hSXO\|YYm=	NYX2[HNCPSEQvF2=	MW[yOEBp	M3Pkd2ROW09?	MnLXTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	NFnGSmEzPTh\|NESwNS=>
MDA-MB-231	NHrYcIVHfW6ldHnvckBCe3OjeR?=	M33WeFUh\|ryP	Mof4NlQhcA>?	NIXOb5lFVVOR	NGHLdINKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	NXXOeIlbOjV6M{S0NFE>
MDA-MB-231	MnvoSpVv[3Srb36gRZN{[Xl?	M2jwWlUh\|ryP	NF:3cYYzPCCq	NULHVW9OTE2VTx?=	NHvNNZdKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFU{	M3zW[FI2QDN2NECx
MCF7	NFXPS\|lCeG:ydH;zbZMhSXO\|YYm=	NX3uVIViPSEQvF2=	NYfDOmFVOjRiaB?=	MnXySG1UVw>?	MoX5TY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	Mme5NlU5OzR2MEG=
MDA-MB-231	MoLIRZBweHSxc3nzJGF{e2G7	NIjkVVc2KM7:TR?=	M1zwc\|I1KGh?	M4PhPGROW09?	NIfEdphKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	NXjvToJpOjV6M{S0NFE>
MCF7	MV\GeY5kfGmxbjDBd5NigQ>?	M1O3blEh\|ryP	NVzwV5F3PzJiaB?=	MkPXSG1UVw>?	MnXyTY5lfWOnczDheZRweGijZ3njJIRm[XSq	MkLJNlU5OzR2MEG=
MDA-MB-231	MUTGeY5kfGmxbjDBd5NigQ>?	M3TCeVEh\|ryP	NY\OSXZUPzJiaB?=	MoLBSG1UVw>?	NGjaUoZKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi=	MVmyOVg{PDRyMR?=
U-2 OS	NFPnTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHroWWM2OCEQvF2=	NU[5VlIxOjRiaB?=	MVnEUXNQ	NY\p[2FoUUN3ME2xOk43KM7:TR?=	MofmNlU4QTJ6MUG=
MG-63	M{nESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTFOVAh\|ryP	MnrXNlQhcA>?	MULEUXNQ	MWrJR\|UxRTlwNTFOwG0>	NH\JcHUzPTd7MkixNS=>
U-2 OS	NX3xXVQySXCxcITvd4l{KEG\|c3H5	M13JR\|Uh\|ryP	NF;ZdVAzPCCq	NFvBZmFFVVOR	MonjTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=>	Mnv4NlU4QTJ6MUG=
MG-63	NX65RpNESXCxcITvd4l{KEG\|c3H5	NUfN[GdYPSEQvF2=	MkThNlQhcA>?	MWHEUXNQ	M4XXfGlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg>	M3vDdVI2Pzl{OEGx
U-2 OS	NH;YcoNHfW6ldHnvckBCe3OjeR?=	NV36WIdIPSEQvF2=	NWLaV5dJOjRiaB?=	NYTodppZTE2VTx?=	M3HQdXBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	NHXiS4IzPTd7MkixNS=>
MG-63	M1TaW2Z2dmO2aX;uJGF{e2G7	MWS1JO69VQ>?	NWnUcIl1OjRiaB?=	NG\lNXZFVVOR	MoHEVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	NV7v[XdlOjV5OUK4NVE>
PANC-1	NHHRVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ThUFUxKM7:TR?=	NF7kcXMzPCCq	Ml3USG1UVw>?	M3;BZ2lEPTB;Nz6xJO69VQ>?	MYeyOVY{OjJ{NR?=
BxPC-3	NX3MUGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO4fI5jPTBizszN	NGixNW0zPCCq	NFXWV3VFVVOR	MXHJR\|UxRTZwODFOwG0>	M{HJeVI2PjN{MkK1
PANC-1	MWfGeY5kfGmxbjDBd5NigQ>?	NVfyWoVQPSEQvF2=	MVKyOEBp	M4\tfmROW09?	MUjJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U>	MWeyOVY{OjJ{NR?=
BxPC-3	M{LzUmZ2dmO2aX;uJGF{e2G7	MlX0OUDPxE1?	M1m5c\|I1KGh?	M1niVWROW09?	NFe0RZVKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V?	M{HBVlI2PjN{MkK1
PANC-1	NYHaeZdpTnWwY4Tpc44hSXO\|YYm=	NETLTpU2KM7:TR?=	NXe1bIhKOjRiaB?=	Mof5SG1UVw>?	M3nKRmlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	M1\xcFI2PjN{MkK1
BxPC-3	MVrGeY5kfGmxbjDBd5NigQ>?	MmHnOUDPxE1?	MWGyOEBp	M3jkcWROW09?	MlPVTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg>	NHfUOpkzPTZ\|MkKyOS=>
SKOV3	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPmWnY{OTByIN88US=>	MkW1NlQhcA>?	MmXISG1UVw>?	NGjoT\|JKSzVyPUKwMlQ5KM7:TR?=	M{DIZlI2PjJ2N{Ww
OVCAR4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XGPFExOCEQvF2=	MVGyOEBp	MnHkSG1UVw>?	M4DlR2lEPTB;MkKuNVMh\|ryP	NHvFWZQzPTZ{NEe1NC=>
SKOV3	MnzoSpVv[3Srb36gRZN{[Xl?	NXTFfWhwPSEQvF2=	NUL4fJdMPzJiaB?=	NV3WfJpLTE2VTx?=	MUPJcoR2[2W\|IFeyM20h[XK{ZYP0	NH7p[3ozPTZ{NEe1NC=>
OVCAR4	MlPnSpVv[3Srb36gRZN{[Xl?	Mnu2OUDPxE1?	M1zyUVczKGh?	MWXEUXNQ	MYXJcoR2[2W\|IFeyM20h[XK{ZYP0	MnTuNlU3OjR5NUC=
SKOV3	NVvIO3Q6SXCxcITvd4l{KEG\|c3H5	NGTGe3g2KM7:TR?=	M{PY[FI1KGh?	M4TNdmROW09?	MWDJcoR2[2W\|IHHwc5B1d3Orcx?=	NHHUUJgzPTZ{NEe1NC=>
OVCAR4	NYrDbVY3SXCxcITvd4l{KEG\|c3H5	NUTw[INrPSEQvF2=	NHLiOWozPCCq	NELab5hFVVOR	NYHxcWgzUW6mdXPld{BieG:ydH;zbZM>	MXmyOVYzPDd3MB?=
AGS	NHHEe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fpU\|I2KM7:TR?=	NGrYVGozPCCq	MkfKSG1UVw>?	NEe3RmFKSzVyPUG5MlA6KM7:TR?=	M13RPVI2PjB7OUKz
NCI-N78	M2npRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2W4[\|I2KM7:TR?=	NFm0U\|kzPCCq	M3\yRmROW09?	NIP4XYtKSzVyPUK2MlM{KM7:TR?=	NWLMPWxwOjV4MEm5NlM>
AGS	NWLQc5Z3SXCxcITvd4l{KEG\|c3H5	MVO1JO69VQ>?	MmHsNlQhcA>?	NEnJb2NFVVOR	MoPNTY5lfWOnczDhdI9xfG:\|aYO=	MUSyOVYxQTl{Mx?=
NCI-N78	NGTiUotCeG:ydH;zbZMhSXO\|YYm=	M4[4XVUh\|ryP	MVWyOEBp	MmHhSG1UVw>?	NWrF[GtuUW6mdXPld{BieG:ydH;zbZM>	NIrpUXozPTZyOUmyNy=>
AGS	MXHGeY5kfGmxbjDBd5NigQ>?	NEfjdoQ2KM7:TR?=	MnnjNlQhcA>?	NVTI[\|NiTE2VTx?=	NFiwXG5KdmS3Y3XzJJRp\SCjdYTvdIhi\3l?	Ml\xNlU3ODl7MkO=
NCI-N78	NIDPenVHfW6ldHnvckBCe3OjeR?=	Ml3DOUDPxE1?	MWWyOEBp	M3PHSWROW09?	Mn\uTY5lfWOnczD0bIUh[XW2b4DoZYd6	MWmyOVYxQTl{Mx?=
HSC-3	NVXod49pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmq2NUDPxE1?	MWC0PEBp		MXTJR\|UxRTBwNUSg{txO	MmDoNlU{PjZzNEO=
GB30	M2ri[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;DNUDPxE1?	M4PJfFch\A>?	M{XSS2ROW09?	MmTSTWM2OD1yLkCxNUDPxE1?	NEHsO4gzPTFyNkSyPC=>
GB9	NV6zZ4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\rZopwOSEQvF2=	NYLVdHJuPyCm	M1\tcWROW09?	Moq5TWM2OD1yLkCyOEDPxE1?	NV75VJkzOjVzME[0Nlg>
GB169	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PPbVEh\|ryP	NUP6[FZkPyCm	NGOyTo5FVVOR	NIXhTYJKSzVyPUCuNFMzKM7:TR?=	MWCyOVExPjR{OB?=
T24	MYDGeY5kfGmxbjDBd5NigQ>?	NYLI[nlWOSEQvF2=	M3GxcVQ5KGh?	MUfEUXNQ	M4W5fWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NVT2UJBtOjN2MEO2N\|M>
RT4	NXfvSGF5TnWwY4Tpc44hSXO\|YYm=	NF7iTJkyKM7:TR?=	MV60PEBp	M3\YWmROW09?	M4XvOmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NW\5V2hzOjN2MEO2N\|M>
UM-UC-3	NIT3e4RHfW6ldHnvckBCe3OjeR?=	M170WFEh\|ryP	MmnmOFghcA>?	MXvEUXNQ	MkC0TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dB?=	NXm0R25UOjN2MEO2N\|M>
T24	NGPUO5VCeG:ydH;zbZMhSXO\|YYm=	MYqzMlE3KM7:TR?=	Ml7GPVYhcA>?	M{\QOWROW09?	M2XTc2lEPTB;MD6wN\|A3KM7:TR?=	NUHzenhOOjN2MEO2N\|M>
RT4	Mme4RZBweHSxc3nzJGF{e2G7	MkPCN{4yPiEQvF2=	NXO1dFlsQTZiaB?=	MVzEUXNQ	MkDWTWM2OD1yLkGxPVgh\|ryP	M1\pOFI{PDB\|NkOz
UM-UC-3	MkHGRZBweHSxc3nzJGF{e2G7	MmDxN{4yPiEQvF2=	M2rBUlk3KGh?	NVnoOWQxTE2VTx?=	MmW0TWM2OD1yLkC0OFkh\|ryP	NWDGTmRLOjN2MEO2N\|M>
OVCAR-5	MnnZSpVv[3Srb36gRZN{[Xl?	NUDBNmdVPTBibl2=			M3jQfmlvcGmkaYTzJINmdGxibXnndoF1cW:w	NGDqeXYzOzN\|NEOyOy=>
SKOV3ip2	Mnr0SpVv[3Srb36gRZN{[Xl?	MoDyOVAhdk1?			MmPkTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25?	MUeyN\|M{PDN{Nx?=
S462	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nwW\|ExOCEQvF2=	MYG3NkBp	NIPWepJFVVOR	MXXBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	NInlV\|kzOzN{OEGxOC=>
2884	NYjMUWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPoNVAxKM7:TR?=	NH;QSo84OiCq	NYPnVJRXTE2VTx?=	MoKzRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>?	MXmyN\|MzQDFzNB?=
2885	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOxNFAh\|ryP	MoH3O\|IhcA>?	NIfm[GFFVVOR	M1S4d2F1fGWwdXH0[ZMh[2WubDDndo94fGh?	MmXRNlM{OjhzMUS=
CRL-2396	NV;pbXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;NR\|BDOTByIN88US=>		M{DsXZdifGW{	M4rRNmlEPTB;MD6wPVIh\|ryP	MWiyN\|E2OzV{NB?=
TIB-48	NYDHNWtRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrzSY0yODBizszN		Mmq5e4F1\XJ?	MWfJR\|UxRTBwMEi4JO69VQ>?	MW[yN\|E2OzV{NB?=
CRL-2396	M2P3R2N6fG:2b4jpZ{BCe3OjeR?=	MUixJO69VQ>?	NXe4R5lXPDhiaB?=	M{LlN5difGW{	MWrJcoR2[2W\|IHHwc5B1d3Orcx?=	MnjMNlMyPTN3MkS=
TIB-48	MlvRR5l1d3SxeHnjJGF{e2G7	M4PYWlEh\|ryP	M3[1NVQ5KGh?	NIfsWmR4[XSnch?=	NVGzT5FuUW6mdXPld{BieG:ydH;zbZM>	Mk\UNlMyPTN3MkS=
AGS	NGHVc\|dEgXSxdH;4bYMhSXO\|YYm=	MX2wMlUh\|ryP	NWW1TnYxOjRiaB?=	NWf5RYdXTE2VTx?=	NWrERWVkTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	NXTsS4w3OjJ7N{K2NVE>
FLO-1	MWHDfZRwfG:6aXOgRZN{[Xl?	Mof5NE42KM7:TR?=	MmPmNlQhcA>?	MlzCSG1UVw>?	NUDR[5V4TGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	NV[2VW5qOjJ7N{K2NVE>
OE33	NXrUbHBWS3m2b4TvfIlkKEG\|c3H5	M3P1dlAvPSEQvF2=	NGSz[4szPCCq	M1;mUmROW09?	MVXE[YNz\WG\|ZYOgZ4VtdCC\|dYL2bZZidA>?	MUiyNlk4OjZzMR?=
SKLMS	NHy5c41EgXSxdH;4bYMhSXO\|YYm=	MYi3OUBvVQ>?	MmHHPVYhcA>?		NInjbnFKdmS3Y3XzJIFxd3C2b4Ppdy=>	NELSdIkzOjh{MUm5Oy=>
Leio285	M4G4b2N6fG:2b4jpZ{BCe3OjeR?=	Ml;yO\|Uhdk1?	MmSzPVYhcA>?		M3rJUWlv\HWlZYOgZZBweHSxc3nz	NV;CPZYxOjJ6MkG5PVc>
Mes-Sa	MV\DfZRwfG:6aXOgRZN{[Xl?	NE\TWGY4PSCwTR?=	Mkm1PVYhcA>?		M{fa[Glv\HWlZYOgZZBweHSxc3nz	NGTZWZYzOjh{MUm5Oy=>
DAOY	NYXGbW9KS3m2b4TvfIlkKEG\|c3H5	MoPaNVAh\|ryP	M4jSRlczKGh?	NVXBfYZpTE2VTx?=	MnvWTWM2OD1yLkC0JO69VQ>?	NGHuWVAzOjZ4OUOzOS=>
IMR32	M3rESWN6fG:2b4jpZ{BCe3OjeR?=	M13qeFExKM7:TR?=	MnzrO\|IhcA>?	NUPnOnVqTE2VTx?=	Moq2TWM2OD1yLkCzJO69VQ>?	MYmyNlY3QTN\|NR?=
Molt-4	MoTJR5l1d3SxeHnjJGF{e2G7	NYrzcphlOTBizszN	M1TnTFczKGh?	NWfYfmlCTE2VTx?=	NVfDN3VvUUN3ME2wMlAzKM7:TR?=	MlrWNlI3Pjl\|M{W=
MOLM-13	NHKyV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT1N{DPxE1?	MnXkO\|IhcA>?		NGXDdlBFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NWfVZoNWOjJ2OEiyOFk>
HL-60	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzYN{DPxE1?	NIe5SIY4OiCq		M3eyR2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NFu2OG8zOjR6OEK0PS=>
MV4-11	M1P5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGzJO69VQ>?	NF;lNpM4OiCq		MoHSSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	M2C2XFIzPDh6MkS5
SKM-1	NY\xbFZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PPPFMh\|ryP	M2O5W\|czKGh?		M3foVGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	MV2yNlQ5QDJ2OR?=
SH2	M{PST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG0OWdqOyEQvF2=	NVvyUoZQPzJiaB?=		MmDpSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	MlS5NlI1QDh{NEm=
NOMO-1	M1XUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vwO\|Mh\|ryP	MW[3NkBp		NH\OfZVFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NGTBbIEzOjR6OEK0PS=>
OCL-AML2	M4rxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fMRVMh\|ryP	MoPxO\|IhcA>?		M2K5NmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	MXGyNlQ5QDJ2OR?=
PL-21	NX:2Z3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGntZ40{KM7:TR?=	MVO3NkBp		MXjEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MX2yNlQ5QDJ2OR?=
KG-1	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC4N{DPxE1?	MmTFO\|IhcA>?		MYjEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MUSyNlQ5QDJ2OR?=
A172	NX;vT41OS3m2b4TvfIlkKEG\|c3H5	NHzEZ\|UyODBizszN	NVH0WHp[OjRiaB?=	NEXNXZBFVVOR	MVnJR\|UxRTBwMUKwJO69VQ>?	NGG3ZVczOjJ5NEO5PS=>
U87	NXLOVnNDS3m2b4TvfIlkKEG\|c3H5	NWPhUpdqOTByIN88US=>	NF;iV3IzPCCq	M1TNUWROW09?	NF\GeIhKSzVyPUCuNVA2KM7:TR?=	M3HIZVIzOjd2M{m5
U251	MUPDfZRwfG:6aXOgRZN{[Xl?	M1SxR\|ExOCEQvF2=	NWLHO2pyOjRiaB?=	NX7KfVFvTE2VTx?=	MVrJR\|UxRTBwMUCwJO69VQ>?	NFrNTJkzOjJ5NEO5PS=>
T98	NFP6NFlEgXSxdH;4bYMhSXO\|YYm=	NHLtV\|MyODBizszN	NXHYeJZ[OjRiaB?=	M3m2emROW09?	Mn33TWM2OD1yLkGyOUDPxE1?	NFfEOGczOjJ5NEO5PS=>
LN18	MoTLR5l1d3SxeHnjJGF{e2G7	NEXUeogyODBizszN	Mnn1NlQhcA>?	MXnEUXNQ	NHXlfFhKSzVyPUCuNlExKM7:TR?=	MV:yNlI4PDN7OR?=
LN443	MkTlR5l1d3SxeHnjJGF{e2G7	MoG2NVAxKM7:TR?=	NX2zUJE3OjRiaB?=	MV3EUXNQ	MmjmTWM2OD1yLkKyNEDPxE1?	NW\3[nZkOjJ{N{SzPVk>
HF66	NFiwOphEgXSxdH;4bYMhSXO\|YYm=	NVvxXXIxOTByIN88US=>	NWTpb3pQOjRiaB?=	NUHZepZXTE2VTx?=	NGH1[XZKSzVyPUCuNlI2KM7:TR?=	NIDDfnQzOjJ5NEO5PS=>
HF2303	NWLqV5FtS3m2b4TvfIlkKEG\|c3H5	NYGyTZpMOTByIN88US=>	NILTbm0zPCCq	NUOwcnpmTE2VTx?=	MWXJR\|UxRTBwME[wJO69VQ>?	M1HEcVIzOjd2M{m5
HF2359	MlvkR5l1d3SxeHnjJGF{e2G7	M1LtPVExOCEQvF2=	NVTGbZlbOjRiaB?=	NGexe2pFVVOR	NWHPbFJUUUN3ME2wMlA3OCEQvF2=	M4HJeVIzOjd2M{m5
HF2414	MW\DfZRwfG:6aXOgRZN{[Xl?	NV;odVh6OTByIN88US=>	MXyyOEBp	NILSfXpFVVOR	Mn7DTWM2OD1yLkC4NEDPxE1?	NFvYPZozOjJ5NEO5PS=>
A-673	M3K5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPDNVAh\|ryP	NVnVNlJ2QTZiaB?=	MorHSG1UVw>?	MUDJR\|UxRTBwMEOyJO69VQ>?	NVXsTZQ1OjF2NEi1PVE>
TC-32	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX[0b3NiOTBizszN	MlXZPVYhcA>?	M1vCTmROW09?	M{XpN2lEPTB;MD6wN\|kh\|ryP	M{\UeFIyPDR6NUmx
TC-71	M4L6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnGNVAh\|ryP	MVW5OkBp	M1rVZ2ROW09?	NYDLfnhNUUN3ME2wMlExOiEQvF2=	MV:yNVQ1QDV7MR?=
SK-N-MC	M3vmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnEeZIyOCEQvF2=	MUi5OkBp	NHnYT\|NFVVOR	NWHBeHJNUUN3ME2wMlA4OiEQvF2=	NH;meJQzOTR2OEW5NS=>
CHLA-9	NVzLPGExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyxNEDPxE1?	MXO5OkBp	MXHEUXNQ	NGjDNolKSzVyPUCuNFE5KM7:TR?=	M1LsSVIyPDR6NUmx
CHLA-10	NUnacWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYGzPFVMOTBizszN	MX[5OkBp	MluySG1UVw>?	MXXJR\|UxRTBwME[wJO69VQ>?	NYjvdHB[OjF2NEi1PVE>
CHLA-25	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nFOlExKM7:TR?=	MX65OkBp	MlfJSG1UVw>?	MkfwTWM2OD1yLkG2PEDPxE1?	NI\QdoUzOTR2OEW5NS=>
CHLA-32	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7BNVAh\|ryP	M3XD[\|k3KGh?	MUTEUXNQ	MUnJR\|UxRTBwMUO2JO69VQ>?	MX2yNVQ1QDV7MR?=
CHLA-56	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLDNWcyOCEQvF2=	NGHNNnc6PiCq	MUjEUXNQ	MV\JR\|UxRTFyIN88US=>	M2W2fVIyPDR6NUmx
CHLA-258	Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXLbXUyOCEQvF2=	NF\qXXg6PiCq	Ml3VSG1UVw>?	NXrmZYpqUUN3ME2wMlE{OiEQvF2=	MUOyNVQ1QDV7MR?=
COG-E-352	NXKyW5BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLtenM1OTBizszN	NIn6PVk6PiCq	MWDEUXNQ	M1T5NmlEPTB;MD6wOFMh\|ryP	MnHVNlE1PDh3OUG=
CHLA-90	NVPPfoliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVywWJN6OTBizszN	MnHaPVYhcA>?	NVLBWJQ3TE2VTx?=	NYX6XY5YUUN3ME2wMlA3OSEQvF2=	MWKyNVQ1QDV7MR?=
CHLA-119	NYXPb\|J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDXR4J[OTBizszN	MV25OkBp	NXTFdlN4TE2VTx?=	MWXJR\|UxRTBwMEKyJO69VQ>?	NUiwTIQyOjF2NEi1PVE>
CHLA-122	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	MUC5OkBp	M2rJPWROW09?	MlWxTWM2OD1yLkCxPUDPxE1?	NWK0UG1JOjF2NEi1PVE>
CHLA-136	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1e3S\|ExKM7:TR?=	MY[5OkBp	MYXEUXNQ	MYXJR\|UxRTBwMEO5JO69VQ>?	MXSyNVQ1QDV7MR?=
CHLA-140	NInSWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUGxNEDPxE1?	NYjuO4RkQTZiaB?=	NEH3b\|dFVVOR	NYTyNIppUUN3ME2wMlAzPiEQvF2=	NXLZe\|FlOjF2NEi1PVE>
LA-N-6	NEjPNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn2WIsyOCEQvF2=	M{HP[Vk3KGh?	M3XYcGROW09?	NFnrOItKSzVyPUCuNFU1KM7:TR?=	NV:2dmQyOjF2NEi1PVE>
NB-1643	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxNEDPxE1?	NEC2WXQ6PiCq	NIixTXJFVVOR	M3H5W2lEPTB;MD6wN\|ch\|ryP	NX;0WpM{OjF2NEi1PVE>
NB-EBc1	NX[1O4x[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDPOnAyOCEQvF2=	MYC5OkBp	NYrNUG5CTE2VTx?=	Mnr2TWM2OD1yLkC1NEDPxE1?	NITqSZQzOTR2OEW5NS=>
SK-N-BE-1	M33oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKxNEDPxE1?	NFfiOZQ6PiCq	NWDs[\|IxTE2VTx?=	M1\hWWlEPTB;MD6wNlgh\|ryP	M4qwdlIyPDR6NUmx
SK-N-BE-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuxNEDPxE1?	MYq5OkBp	NUe3XlR5TE2VTx?=	MnzjTWM2OD1yLkCzOkDPxE1?	M3;uOFIyPDR6NUmx
SMS-KAN	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfyXI8yOCEQvF2=	M{X0XFk3KGh?	MVPEUXNQ	NIG4RmxKSzVyPUCuNFM1KM7:TR?=	NH;ib2YzOTR2OEW5NS=>
SMS-KANR	NGrD[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEe2ZpkyOCEQvF2=	MXq5OkBp	MXrEUXNQ	Mmj4TWM2OD1yLkCyOkDPxE1?	MXSyNVQ1QDV7MR?=
SMS-KCN	M{XQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInGT\|AyOCEQvF2=	NWq0So1GQTZiaB?=	MYrEUXNQ	M2LIVWlEPTB;MD6wNVkh\|ryP	MXOyNVQ1QDV7MR?=
SMS-KCNR	M33qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[xNEDPxE1?	MU[5OkBp	NV3IOYU5TE2VTx?=	M1na[GlEPTB;MD6wNVAh\|ryP	MXeyNVQ1QDV7MR?=
SMS-LHN	M2XvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrBNVAh\|ryP	MnTNPVYhcA>?	NW\xR2k2TE2VTx?=	NH3VOmlKSzVyPUCuNFMzKM7:TR?=	Mk\jNlE1PDh3OUG=
SMS-MSN	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2e2VlExKM7:TR?=	MUC5OkBp	MX;EUXNQ	M3rJdmlEPTB;MD6wNlIh\|ryP	MmO2NlE1PDh3OUG=
SMS-SAN	NVvaNYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTVblkyOCEQvF2=	MVm5OkBp	NW\z[W5wTE2VTx?=	MUfJR\|UxRTBwMEKwJO69VQ>?	M{j4XVIyPDR6NUmx
Granta-4	NFPUepVEgXSxdH;4bYMhSXO\|YYm=	M13nTlExKM7:TR?=	NUPUTpZrPyCm		M3PuSWlEPTB;MD6wOFAh\|ryP	MoHxNlEzQTF6Nke=
DB	MWHDfZRwfG:6aXOgRZN{[Xl?	MmfJNVAh\|ryP	M4\4PVch\A>?		Mk\lTWM2OD1yLkC0NkDPxE1?	MY[yNVI6OTh4Nx?=
RL	MlTBR5l1d3SxeHnjJGF{e2G7	MoexNVAh\|ryP	MXS3JIQ>		M2[2TmlEPTB;MD6wNVUh\|ryP	M2PCNVIyOjlzOE[3
K562	NF\afppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LqWlExKM7:TR?=	MnfoPVYhcA>?		M{DmW2lEPTB;MD6wPFch\|ryP	NFPRfmYzOTB7MU[zNy=>
LAMA-84	NFqyO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nifFExKM7:TR?=	NHHhNI86PiCq		NUOxO2ZPUUN3ME2wMlA2PyEQvF2=	NVrJ[mpTOjFyOUG2N\|M>
MM15	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPRcYE1KM7:TR?=	NUnidVg5PzJiaB?=	M1GwNGROW09?	MUTJR\|UxRTBwMUOg{txO	NXTWR49mOjB\|OEK4OFQ>
OPM1	NV;NbpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTWOEDPxE1?	NVHRZWNqPzJiaB?=	NE\UWo9FVVOR	NFLZTYtKSzVyPUCuNFMh\|ryP	MV[yNFM5Ojh2NB?=
RPM1	M3O0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3oVG5bPCEQvF2=	M33QZVczKGh?	MnTBSG1UVw>?	Ml7lTWM2OD1zMD6zNkDPxE1?	MYOyNFM5Ojh2NB?=
INA6	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFSz[XU1KM7:TR?=	NETRZXI4OiCq	NEP4R21FVVOR	M1O4PWlEPTB;MD6wNFIh\|ryP	NVjUR2hMOjB\|OEK4OFQ>
OPM2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL5VW01KM7:TR?=	MXu3NkBp	MWjEUXNQ	MkSzTWM2OD12LkO3JO69VQ>?	MXOyNFM5Ojh2NB?=
MM1R	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG2O3o1KM7:TR?=	Mlr6O\|IhcA>?	NGPsO4dFVVOR	MknMTWM2OD1zLk[4JO69VQ>?	NILWV2YzODN6Mki0OC=>
DOX40	NWr0SlA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXe0JO69VQ>?	NXjW[VA1PzJiaB?=	MVjEUXNQ	NHXoWoZKSzVyPUWuOFgh\|ryP	NWG1VWNnOjB\|OEK4OFQ>
LR5	NEXLUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjCWVZSPCEQvF2=	NUfCeJlLPzJiaB?=	NGD6O\|VFVVOR	MV7JR\|UxRTJwNUOg{txO	MmWyNlA{QDJ6NES=
U266	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjLfXA1KM7:TR?=	NFfzWnE4OiCq	NGC3[oNFVVOR	MYPJR\|UxRTFwNEOg{txO	NIWyUlQzODN6Mki0OC=>
RD	M1vuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHIVFZGOTBizszN	NU[3XG1pQTZiaB?=		MlHHTWM2OD1yLkKyPEDPxE1?	NVP6O5ZzOjBzMEizN\|g>
Rh41	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fJcFExKM7:TR?=	NELkOY06PiCq		NVnIdW16UUN3ME2wMlA6OCEQvF2=	MV[yNFExQDN\|OB?=
Rh30	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrtUXcyOCEQvF2=	M3vWelk3KGh?		NF3MeIJKSzVyPUCuNlMxKM7:TR?=	MojPNlAyODh\|M{i=
BT-12	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXCcosyOCEQvF2=	Mne5PVYhcA>?		NWjZWYc5UUN3ME2wMlA3OCEQvF2=	NHLST2szODFyOEOzPC=>
CHLA-266	M2jNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCxNEDPxE1?	M3rQclk3KGh?		MmfVTWM2OD1yLkC3NkDPxE1?	M3TvSlIxOTB6M{O4
TC-71	M1j4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHBNVAh\|ryP	NWPNclU3QTZiaB?=		NVzJPGh4UUN3ME2wMlExOiEQvF2=	MorWNlAyODh\|M{i=
SJ-GBM2	M2TJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHBNVAh\|ryP	Mo\0PVYhcA>?		MnTlTWM2OD1yLkC1NEDPxE1?	MnrENlAyODh\|M{i=
NALM-6	M1nobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHTdVZ3OTBizszN	MY[5OkBp		Mkn0TWM2OD1yLkC2NkDPxE1?	M1;6eVIxOTB6M{O4
COG-LL-317	NX;qfGxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInQZnEyOCEQvF2=	NHfhWm46PiCq		MVTJR\|UxRTBwMES3JO69VQ>?	MoTXNlAyODh\|M{i=
RS4-11	NVnWV2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TpPFExKM7:TR?=	NXW0eFhjQTZiaB?=		MWfJR\|UxRTBwMEG4JO69VQ>?	M{fTNFIxOTB6M{O4
MOLT-4	NFvxb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLyVWFGOTBizszN	NVqyT3dRQTZiaB?=		NHLuZ5RKSzVyPUCuNFI3KM7:TR?=	MYKyNFExQDN\|OB?=
CCRF-CEM	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TORlExKM7:TR?=	M{LNRlk3KGh?		NGPiT25KSzVyPUCuNFk1KM7:TR?=	MlTFNlAyODh\|M{i=
Kasumi-1	NU\DZpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPCSIkyOCEQvF2=	M{S2VVk3KGh?		NEXzWWNKSzVyPUCuNVA{KM7:TR?=	MkHjNlAyODh\|M{i=
Karpas-299	M3XO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULEPGxHOTBizszN	MYG5OkBp		M2PoeGlEPTB;MD6wN\|gh\|ryP	Mmi2NlAyODh\|M{i=
Ramos-RA1	NF3i[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWeyemV{OTBizszN	M3LYVlk3KGh?		NHzHO3RKSzVyPUCuNVI4KM7:TR?=	MmTlNlAyODh\|M{i=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

In vivo

MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-³³P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:^[2]	- Collapse Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24, 48, and 72 hours Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using ³[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate Dosages: ~30 mg/kg/day Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+30% PEG300+5%Tween-80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Alisertib (MLN8237) SDF

Molecular Weight	518.92
Formula	C₂₇H₂₀ClFN₄O₄
CAS No.	1028486-01-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the suggested formulation of this compound for mouse injection(i.p.)?
Answer:
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitor

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitor

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Barasertib (AZD1152-HQPA，AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Tozasertib (VX-680, MK-0457)

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)

Cited by 198 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Alisertib (MLN8237) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)

Cited by 198 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Alisertib (MLN8237) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)